When was abreva introduced

J Esthet Restor Dent. Published online Apr Author information Copyright and License information Disclaimer. Reprint requests: William D. Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.

This article has been cited by other articles in PMC. Abstract Statement of the Problem Rapid resolution of active herpes labialis lesions is of great benefit to the patient not only in terms of controlling pain and disfigurement, but in disruption of needed dental treatment.

Purpose of the Study Using three groups, this retrospective study investigated the time required to complete healing and the loss of discomfort. Results For both the time to healing and time to loss of discomfort, participants in both the Abreva and Viroxyn groups experienced significant improvements. Conclusion Relative to the untreated controls, both Abreva and Viroxyn offered a significant reduction in both the time to healing and time to loss of discomfort. J Esthet Restor Dent —, Open in a separate window.

Specifically, the primary outcome objectives studied were: Time to persistent resolution of discomfort pain, itching, and burning. Time to healing loss of hard scab and return to intact skin.

Survey First participants were asked to provide their initials for identification purposes, basic demographic data, and an estimate of how many cold sores they experience per year. For the time to loss of pain, participants were offered the following responses: 2 minutes 0. Statistical Analysis Plan All participants who returned a survey with at least one data point showing outcome data for either drug were included in the analysis.

Table 2 Distribution of responses. Table 3 Days until healed. Definition: loss of hard scab and return to intact skin. Table 4 Days until loss of discomfort.

Participant Who Have Used Viroxyn but Never Used Abreva The number of cold sores per year Table 2 is also consistent with the literature values, 1 , 3 — 5 and the demographics data are similar as well Table 2. Study Design-Induced Bias Favors Abreva For the time to healing and time to loss of discomfort, data were censored or cut off at an artificial point. Snoeck R, De Clercq E. Treatment of herpes simplex virus infections. Infect Med. Increasing proportion of herpes simplex virus type-1 as a cause of genital herpes 3 infections in college students.

Sex Transm Dis. Miller C, Redding S. Diagnosis and management of orofacial herpes simplex virus infections. Dent Clin North Am. The natural history of recurrent oral-facial herpes simplex virus infection. J Infect Dis. April [ PubMed ] [ Google Scholar ]. Esmann J. The many challenges of facial herpes simplex virus infection.

J Antimicrob Chemother. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis; a randomized double blind placebo-controlled trial. Clin Ther. Essentials of oral medicine. Drug information handbook for dentistry. The information contained in the PMPRB's Summary Reports should not be relied upon for any purpose other than stated and is not to be interpreted as an endorsement, recommendation or approval of any drug nor is it intended to be relied upon as a substitute for seeking appropriate advice from a qualified health care practitioner.

Antiviral agents for the treatment of common herpetic infections in immunocompetent patients. Pharmacist's letter. December DN Antiviral Agents Bull ; New phase III trials with lidakol for oral herpes.

Topical Lidakol efficacy comparable to acyclovir cream for oral herpes Antiviral Agents Bull ; Accessed 21 March Anti-infective Review Panel. Anti-infective Guidelines for Community-acquired Infections. Toronto, ON. Aoki FY. Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: Four approved indications and 13 off label uses.

Can J Infect Dis ;14 1 Based on a data review that included demographics, search, behavioral patterns, purchase history, and lifestyle interests, four main segments emerged and formed the basis for how Abreva developed its creative idea and delivered its campaign :.

Abreva knew that running an edited version of its second TV commercial on mobile would not work. The campaign ran on YouTube, which provided two advantages :. When early sufferers casually searched on YouTube, a programmatically tailored ad appeared. Their affinity profile determined the video concept and call to action, and their real-time search intent instigated the initial headline. The campaign was designed and developed entirely for mobile because Abreva knew its assets for this audience would be seen on a mobile device percent of the time.

You are leaving the Abreva. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link. GSK is not responsible for, does not recommend and accepts no liability for any information or opinion contained in any third-party website. Skip to Content link. Find answers to frequently asked questions about Abreva Cream, cold sore treatment instructions and much more. Abreva cream comes in a tube or pump, and uses the same formula.

The tube is perfect to use at home. To use the Abreva pump for the first time, simply take the top off and press the pump 6 to 8 times to get the first dose. Each time after, just gradually press the pump for the amount you need. You can then apply the cream with a cotton swab or your finger by rubbing it in gently, and the cream will dry clear. But do wash your hands before and after applying the cream. The pump is designed to dispense the right amount of cream for one application.

More cream may be needed when a cold sore is large and less as it gets smaller.